Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by canadapieton Feb 04, 2020 12:05pm

76 Views

Post# 30640253

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Theratechnologies hires Grinspoon for tesamorelin study

I wrote and asked Mr. Tanguay !!!
Hope to get an answer real fast, so we know where we are at!!!
If what "qwerty" and some others are suggesting is true, then (i dare not
think about it can be possible.....) he lied !!!

They already met with the FDA and were waiting for an answer of them (he
said literally "with the FDA you are never sure of the timeline, therefore the
end of 1 H mention). They were waiting for an answer and were confident
they could answer every possible question from the FDA !!!!

All the best, sincerely

Canadapiet

qwerty22 - (2/4/2020 11:54:05 AM)
RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Theratechnologies hires Grinspoon for tesamorelin study

I think the confusion is about timing and the statement about Grinspoon helping with the regulators.

If you are correct that the meeting has happened already then why put that statement in the PR? If the company have signalled that the meeting has already happened then why put that statement in the PR?

It doesn't all quite add up.

In my mind they've clear missed their earlier expectation of fda talks at the end of 2019/ early 2020. The statement that shifted discussions to H1 rather than Q1 is more consistent with today's announcement.

The FDA meeting MUST still be ahead of us. Accept that and the confusion disappears. Then we can start the usual discussion on who to blame!